China Resources Pharmaceutical Subsidiary Completes Issuance of RMB900 Million Corporate Bonds

Stock News10-16

China Resources Pharmaceutical Group Ltd (HKEX: 03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Limited, has completed the public issuance of its second tranche of 2026 corporate bonds in China.

The second tranche of 2026 corporate bonds, with a principal amount of RMB900 million, has been issued with a term of three years and a coupon rate of 1.48% per annum.

The net proceeds raised from the issuance of the second tranche of 2026 corporate bonds will be used for productive expenditures, including repayment of corporate debt, replenishment of working capital, project development and operating expenses, investments related to technological innovation, and other purposes that comply with applicable laws and regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment